

COVID-19 Vaccine Update

Webinar 8

Date: May 23rd, 2023

Presentation By:

Allie Staton, PharmD

Vaccine Confidence Strategist

Immunize Arkansas

Email: allie@immunizear.org



UAMS DISCLOSURE POLICY

It is the policy of the University of Arkansas for Medical Sciences (UAMS) to ensure balance, independence, objectivity, and scientific rigor in all directly or jointly provided educational activities.

All individuals who are in a position to control the content of the educational activity (course/activity directors, planning committee members, staff, teachers, or authors of CE) must disclose all relevant financial relationships they have with any commercial interest(s) as well as the nature of the relationship. The ACCME and ACPE describe relevant financial relationships as those in any amount occurring within the past 24 months that create a conflict of interest. *Individuals who refuse to disclose will be disqualified from participation in the development, management, presentation, or evaluation of the CE activity.*

DISCLOSURES

The following planners and speakers of this CE activity have no relevant financial relationships with ineligible companies to disclose:

Allie Staton, PharmD

The accreditation compliance reviewers, Courtney Bryant and Sara Hale, have no relevant financial relationships with ineligible companies to disclose.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



CREDIT DESIGNATION STATEMENTS

AMA Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit Designation Statement

These knowledge based activities will provide pharmacists up to 1.0 contact hours or 0.1 CEU. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.

ANCC Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

AAPA Credit Designation Statement

The University of Arkansas for Medical Sciences has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CONTINUING EDUCATION

To receive Continuing Education:

- **You must attend this webinar as it is being presented.**
 - Attendance will be recorded via Zoom to determine if you were present.
 - If you are watching this as a recording, you will not be eligible to receive CE.
- **You must complete the Evaluation Survey following this webinar.**
 - A link to the Evaluation Survey will be posted in the chat at the end of the presentation.
 - **DEADLINE: Midnight on Wednesday, May 24th**
 - **No late evaluations will be accepted.** Please complete the survey ASAP.
 - The survey link will also be sent out tomorrow afternoon in a follow-up email.
- **Certificates of Completion for attending this course will be available after you complete the Evaluation Survey.**
 - After you complete the survey, you will be directed to Certificates of Completion website.
 - You will have to write your name on the Certificate.
 - A link to the Certificates of Completion will also be sent out tomorrow afternoon in a follow-up email.

WEBINAR

- If you have a question during or after the webinar, please post your question in the chat.
 - We will do our best to answer all questions before the end of the webinar.
- If you have a question after the webinar, please email Allie Staton.
 - allie@immunizear.org

OBJECTIVES

At the end of this webinar, learners will be able to:

- Interpret current COVID-19 vaccine guidelines.
- Recommend appropriate vaccines to patients and community members.
- Discuss current COVID-19 vaccine guidelines and recommendations.

TOPICS

- Review updated pediatric COVID-19 vaccine recommendations
 - Focus on updated recommendations for:
 - Ages 6 years through 11 years
 - Ages 12 years and older

CDC INTERIM CLINICAL CONSIDERATIONS FOR COVID-19 VACCINES

COVID-19 vaccine recommendations are based on:

- Age
- Health Status
 - Healthy versus Immunocompromised
- Previous doses of COVID-19 vaccines

Recommendations for use of COVID-19 vaccines are published on the CDC's website.

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>


CURRENTLY AVAILABLE PRODUCTS

COVID-19 VACCINE PRODUCT REVIEW

Pfizer	Moderna	Janssen / J&J	Novavax
mRNA	mRNA	Adenovirus Vector	Protein Subunit
6 months and older	6 months and older	18 years and older	12 years and older
<p><u>Products</u></p> <p>Monovalent:</p> <ul style="list-style-type: none"> - 6 months thru 4 years - 5 years thru 11 years - 12 years and older <p>Bivalent:</p> <ul style="list-style-type: none"> - 6 months thru 4 years - 5 years thru 11 years - 12 years and older 	<p><u>Products</u></p> <p>Monovalent:</p> <ul style="list-style-type: none"> - 6 months thru 5 years - 6 years thru 11 years - 12 years and older <p>Bivalent:</p> <ul style="list-style-type: none"> - 6 months thru 5 years - 6 months and older 	<p><u>Products</u></p> <p>Monovalent:</p> <ul style="list-style-type: none"> - 18 years and older 	<p><u>Products</u></p> <p>Monovalent:</p> <ul style="list-style-type: none"> - 12 years and older

PFIZER / BIONTECH

	Pfizer Monovalent			Pfizer Bivalent		
	Pfizer Primary Series	Pfizer Primary Series	Pfizer Primary Series	Pfizer Bivalent Primary Series (3 rd dose only)	Pfizer Bivalent Booster	Pfizer Bivalent Booster
Age Group	6 months thru 4 years	5 years thru 11 years	12 years and older	6 months thru 4 years	5 years thru 11 years	12 years and older
Vial Cap and Label color	Cap: Maroon Label Border: Maroon	Cap: Orange Label Border: Orange	Cap: Gray Label Border: Gray	Cap: Maroon Label Border: Maroon	Cap: Orange Label Border: Orange	Cap: Gray Label Border: Gray
Dilution?	YES (2.2 mL)	YES (2.2 mL)	NO	YES (2.2 mL)	YES (1.3 mL)	NO
Dose Volume	0.2 mL	0.2 mL	0.3 mL	0.2 mL	0.2 mL	0.3 mL
Doses per Vial	10	10	6	10	10	6
Expiration	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours



Disclaimer: The information in this chart is subject to change. Please see current Fact Sheets for Healthcare Providers for updated information.

PFIZER / BIONTECH

	Pfizer Bivalent		
	Pfizer Bivalent	Pfizer Bivalent	Pfizer Bivalent
Age Group	6 months thru 4 years	5 years thru 11 years	12 years and older
Vial Cap and Label color	Cap: Maroon Label Border: Maroon	Cap: Orange Label Border: Orange	Cap: Gray Label Border: Gray
Dilution?	YES (2.2 mL)	YES (1.3 mL)	NO
Dose Volume	0.2 mL	0.2 mL	0.3 mL
Doses per Vial	10	10	1 or 6
Expiration	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours	UCF: Good until exp date Freezer: NA Fridge: 10 weeks after UCF Room Temp: 12 hours After Puncture: 12 hours

Disclaimer: The information in this chart is subject to change. Please see current Fact Sheets for Healthcare Providers for updated information.

MODERNA

	Moderna Monovalent			Moderna Bivalent	
	Moderna Primary Series	Moderna Primary Series	Moderna Primary Series	Moderna Bivalent Booster	Moderna Bivalent Booster
Age Group	6 months thru 5 years	6 years thru 11 years	12 years and older	6 months thru 5 years	6 years and older
Vial Cap and Label color	Cap: Blue Label Border: Magenta	Cap: Blue Label Border: Magenta	Cap: Red Label Border: Blue	Cap: Dark Pink Label Border: Yellow	Cap: Blue Label Border: Gray
Dilution?	NO	NO	NO	NO	NO
Dose Volume	0.25 mL	0.25 mL	0.5 mL	0.2 mL	6 – 11 years: 0.25 mL 12 years and older: 0.5 mL
Doses per Vial	10	5	11	2	5
Expiration	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 8 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours

Disclaimer: The information in this chart is subject to change. Please see current Fact Sheets for Healthcare Providers for updated information.

MODERNA

	Moderna Bivalent	
	Moderna Bivalent	Moderna Bivalent
Age Group	6 months thru 5 years	6 months and older
Vial Cap and Label color	Cap: Dark Pink Label Border: Yellow	Cap: Blue Label Border: Gray
Dilution?	NO	NO
Dose Volume	0.2 mL	6 months – 11 years: 0.25 mL 12 years and older: 0.5 mL
Doses per Vial	2	5 to 10 (depends on dose volume)
Expiration	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 8 hours	UCF: NA Freezer: Good until exp date Fridge: 30 days after freezer Room Temp: 24 hours (total) After Puncture: 12 hours

The cartons and labels for both of these products say “**BOOSTER DOSES ONLY**”.

Ignore that...

Always follow EUAs instead of labels on products for COVID-19 vaccines.

NOVAVAX

	Novavax Primary Series	Novavax Booster Dose (same product as primary series)
Age Group	12 years and older	18 years and older
Dilution?	NO	NO
Dose Volume	0.5 mL	0.5 mL
Doses per Vial	10	10
Expiration	UCF: NA Freezer: NA Fridge: Good until exp date Room Temp: NA After Puncture: 6 hours in fridge, or 6 hours at room temp	UCF: NA Freezer: NA Fridge: Good until exp date Room Temp: NA After Puncture: 6 hours in fridge, or 6 hours at room temp

Novavax has a mechanism that is similar to vaccines that have been approved for years.

This vaccine is an option for those who are hesitant about the mRNA technology that was used for the other COVID-19 vaccines.

**See next slide for Booster
Dose Eligibility**

Novavax COVID-19 Vaccine remains authorized to provide:

- A 2-dose primary series to people ages 12 years and older. The primary series doses are separated by 3 weeks.
- A booster dose in limited situations to people ages 18 years and older who previously completed primary vaccination using any FDA-approved or FDA-authorized COVID-19 vaccine; have not received any previous booster dose(s); and are unable (i.e., contraindicated or vaccine not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. The monovalent Novavax booster dose is administered **at least 6 months** after completion of any primary series.

Novavax Booster Eligibility:


- 18 years or older
- Completed primary series of a monovalent product
- 6 months since last dose of primary series
- No booster doses of an mRNA product
- Unable or unwilling to receive an mRNA bivalent booster

CURRENT RECOMMENDATIONS
AGES 6 YEARS AND OLDER

UPDATES

- Monovalent mRNA vaccines are no longer authorized for use.
- CDC recommends that people ages 6 months and older receive at least 1 bivalent mRNA vaccine.
- The number of recommended/authorized bivalent doses varies by:
 - Age
 - Vaccine product
 - Previous COVID-19 vaccines received
 - "Healthy" or "Moderately to Severely Immunocompromised"

New recommendations for people aged ≥ 6 years without immunocompromise who have not yet received a bivalent mRNA dose, regardless of COVID-19 vaccination history



UPDATES

For people who are not moderately or severely immunocompromised:

- People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose.

For people who are moderately to severely immunocompromised:

- At the time of initial vaccination:
 - People ages 6 months and older are recommended to receive 3 bivalent mRNA vaccine doses.
- People ages **6 months** and older who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on age and vaccine product.
 - 3 or more total vaccine doses recommended, with at least 1 dose being bivalent.
- People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1 or more additional bivalent mRNA vaccine doses.

UPDATES

- Everyone ages 6 months and older is eligible for at least one dose of bivalent mRNA vaccine.
 - Most people who have already received one dose of a bivalent mRNA vaccine are not eligible for another dose of bivalent.
- People ages 65 and older are eligible for a second dose of a bivalent mRNA vaccine.
 - Must be at least 4 months after first dose of bivalent.
- Immunocompromised people ages 6 months and older are eligible for additional doses of a bivalent mRNA vaccine.
 - Must be at least 2 months after first dose of bivalent.
- Unvaccinated people ages 6 years and older may receive one dose of a bivalent mRNA vaccine.
 - This is considered a complete “primary series”.
- If someone ages 6 years and older received one dose of a monovalent mRNA vaccine...
 - Must wait 8 weeks, then eligible to receive one dose of a bivalent mRNA vaccine to complete their primary series.

CURRENT RECOMMENDATIONS
(HEALTHY)

COVID-19 Vaccine Recommendations

Healthy Adults: Ages 18 years and older

Date: April 19, 2023




PRIMARY SERIES		ADDITIONAL DOSES	
	Dose 1		Additional Doses
Pfizer Cap: Gray	(primary) Pfizer Bivalent: 0.3 mL		Patients 65 years and older: Wait 4 months → Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
Moderna Cap: Dark Blue Label: Gray	(primary) Moderna Bivalent: 0.5 mL		Patients 65 years and older: Wait 4 months → Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL

	Dose 1		Dose 2		ADDITIONAL DOSES	
Novavax	(primary) Novavax Monovalent: 0.5 mL	Wait 3 – 8 weeks →	(primary) Novavax Monovalent: 0.5 mL	Wait 2 months →	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL	Patients 65 years and older: Wait 4 months → Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL

	Dose 1		ADDITIONAL DOSES	
J & J <i>J&J no longer available</i>	(primary) J&J Monovalent: 0.5 mL		Wait 2 months → (after last monovalent dose)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL Patients 65 years and older: Wait 4 months → Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL

*Novavax may be used as a booster dose in limited situations. Patients must meet ALL of the following criteria to be eligible: 1) 18 years and older 2) completed a primary vaccination using any FDA-approved or FDA-authorized COVID-19 vaccine, 3) have not received any previous booster dose(s), and 4) are unable (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. The Novavax monovalent booster dose is administered at least 6 months after completion of any primary series.

COVID-19 vaccination guidance for people who are not moderately or severely immunocompromised

The COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised is summarized in [Table 1](#); see also [COVID-19 Vaccination Recommendations Infographic](#) .

The schedule is organized by age and COVID-19 vaccination history. It provides the number of bivalent mRNA vaccine doses an individual needs based on COVID-19 vaccine doses previously received, including the number of prior doses, whether the doses were monovalent or bivalent, and the vaccine manufacturer (Moderna, Novavax, or Pfizer-BioNTech).

Most people ages 6 years and older who are not moderately or severely immunocompromised and have received 1 dose of a bivalent mRNA vaccine do not need any further vaccine doses at this time. People ages 65 years and older who received 1 dose of a bivalent vaccine have the option to receive 1 additional dose at least 4 months after the first bivalent dose.

Table 1. Recommended COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised by COVID-19 vaccination history, May 2023

Ages 6–11 years[‡]

COVID-19 vaccination history	Bivalent vaccine	Number of bivalent doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna — <i>or</i> — Pfizer BioNTech	1	0.25 mL/25 ug	Dark blue cap; gray label border	—
		1	0.2 mL/10 ug	Orange	—
1 or more doses monovalent mRNA (no doses bivalent mRNA)	Moderna — <i>or</i> — Pfizer BioNTech	1	0.25 mL/25 ug	Dark blue cap; gray label border	At least 8 weeks after last monovalent dose
		1	0.2 mL/10 ug	Orange	At least 8 weeks after last monovalent dose
2 or more doses monovalent mRNA and 1 dose bivalent mRNA	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA
Ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA

COVID-19 Vaccine Recommendations

Healthy Children and Adolescents: Ages 6 years through 11 years

Date: April 19, 2023



Ages: 6 years thru 11 years				
	COVID-19 Vaccine History			
Pfizer Cap: Orange Age: 5 – 11 years	Unvaccinated		Pfizer Bivalent: 0.2 mL OR Moderna Bivalent: 0.25 mL	
	<hr/>			
Moderna Cap: Dark Blue Label: Gray Age: 6 mo and older	1 or more doses monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.2 mL OR Moderna Bivalent: 0.25 mL	
	2 or more doses monovalent Pfizer and 1 dose <i>bivalent</i> mRNA (Pfizer or Moderna)		NA	
	Ever received 1 dose <i>bivalent</i> Pfizer (regardless of monovalent vaccine history)		NA	
	<hr/>			
	1 or more doses monovalent Moderna	Wait 8 weeks	Pfizer Bivalent: 0.2 mL OR Moderna Bivalent: 0.25 mL	
	2 or more doses monovalent Moderna and 1 dose <i>bivalent</i> mRNA (Moderna or Pfizer)		NA	
Ever received 1 dose <i>bivalent</i> Moderna (regardless of monovalent vaccine history)		NA		

NA = not authorized

COVID-19 Vaccine Recommendations

Healthy Teens and Adults: Ages 12 years and older

Date: April 19, 2023



Ages: 12 years and older						
	COVID-19 Vaccine History				ADDITIONAL DOSES (<i>optional</i>)	
Pfizer Cap: Gray Age: 12 years and older	Unvaccinated		Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL	Up to Date	Patients 65 years and older: Wait 4 months	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	1 or more doses monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL	Up to Date	Patients 65 years and older: Wait 4 months	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
2 or more doses monovalent Pfizer and 1 dose <i>bivalent</i> mRNA (Pfizer or Moderna)		NA				
Ever received 1 dose <i>bivalent</i> Pfizer (regardless of monovalent vaccine history)		NA				
Moderna Cap: Dark Blue Label: Gray Age: 6 mo and older	1 or more doses monovalent Moderna	Wait 8 weeks	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL	Up to Date	Patients 65 years and older: Wait 4 months	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	2 or more doses monovalent Moderna and 1 dose <i>bivalent</i> mRNA (Moderna or Pfizer)		NA			
	Ever received 1 dose <i>bivalent</i> Moderna (regardless of monovalent vaccine history)		NA			

NA = not authorized

*One additional dose of bivalent mRNA vaccine for patients ages 65 and older is *optional*.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 1c. **For Most People (those who are NOT moderately to severely immunocompromised)**

Novavax* (Monovalent vaccine) Type: Protein Sub-Unit			
Age	Vaccination History	Vaccine Schedule[†]	Administer
12 years and older	1 or more doses of monovalent Novavax vaccine	1 dose bivalent mRNA vaccine at least 8 weeks (2 months) after Dose 2 [‡]	Moderna: 0.50 mL/50 <i>ug</i> from the vial with a blue cap and gray label border. OR Pfizer-BioNTech: 0.3 mL/30 <i>ug</i> from the vial with a gray cap
	At least 1 dose of bivalent vaccine	No dose [‡]	No dose [‡]

* Novavax COVID-19 Vaccine remains authorized to provide a 2-dose primary series (separated by at least 4–8 weeks) to people ages 12 years and older. Administer 0.5 mL/5 μ g rS and 50 μ g of Matrix-M™ adjuvant vaccine from a vial with a royal blue cap. A booster dose is authorized in limited situations to people ages 18 years and older who completed the primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable (i.e., vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a dose. This dose is administered at least 6 months after completion of any primary series.

[†] Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

[‡] Adults 65 years of age and older: May receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.

CURRENT RECOMMENDATIONS
(MODERATELY TO SEVERELY IMMUNOCOMPROMISED)

MODERATELY TO SEVERELY IMMUNOCOMPROMISED

Patients who meet the following criteria are eligible for additional doses of COVID-19 vaccine products.

Moderately to Severely Immunocompromising Conditions:

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant
 - Within 2 years of transplantation or taking immunosuppression therapy
- Moderate or severe primary immunodeficiency
 - e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome
- Advanced or untreated HIV infection
 - People with HIV and CD4 cell counts $<200/\text{mm}^3$, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV

Moderately to Severely Immunocompromising Treatments:

- High-dose corticosteroids
 - $\geq 20\text{mg}$ prednisone or equivalent per day when administered for ≥ 2 weeks
- Alkylating agents
- Antimetabolites
- Transplant-related immunosuppressive drugs
- Cancer chemotherapeutic agents classified as severely immunosuppressive
- TNF blockers
- Other biologics that are immunosuppressive or immunomodulatory

MODERATELY TO SEVERELY IMMUNOCOMPROMISED

Self-attestation of immunocompromised status

People can self-attest to their moderately or severely immunocompromised status and receive COVID-19 vaccine doses wherever vaccines are offered. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation.

UPDATES – IMMUNOCOMPROMISED

- Immunocompromised people ages 6 months and older are eligible for additional doses of bivalent mRNA vaccines.
 - Must be at least 2 months after first dose of bivalent.

Pfizer

Ages 5 years and older:




- One additional dose of bivalent Pfizer at least 2 months after last dose of bivalent mRNA vaccine.

Moderna

Ages 6 years and older:

- One additional dose of bivalent Moderna at least 2 months after last dose of bivalent mRNA vaccine.

COVID-19 vaccination guidance for people who are moderately or severely immunocompromised

To assist healthcare providers, the COVID-19 vaccination schedule for people who are moderately or severely immunocompromised ([Table 2](#)) provides detailed age-specific guidance; see also [COVID-19 Vaccination Recommendations Infographic \(Immunocompromised\)](#) . However, the EUAs for [Moderna](#)  and [Pfizer-BioNTech](#)  COVID-19 vaccines allow healthcare providers flexibility for use of vaccine products, number of doses, dosage, and intervals between doses; alternative schedules within the parameters of the EUAs may be appropriate based on individual circumstances and clinical judgement.

People who are or who become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule according to their age and immune status at the time of eligibility for that dose; see [Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies](#) for vaccination of people who will shortly become moderately or severely immunocompromised (e.g., prior to organ transplant) and [Considerations for COVID-19 revaccination](#).

Table 2. Recommended COVID-19 vaccination schedule for people who are moderately or severely immunocompromised by COVID-19 vaccination history, May 2023

COVID-19 Vaccine Recommendations

Immunocompromised Children and Adolescents: Ages 6 years through 11 years

Date: April 19, 2023



Ages: 6 years thru 11 years								
	COVID-19 Vaccine History							
Pfizer Cap: Orange Age: 5 – 11 years Moderna Cap: Dark Blue Label: Gray Age: 6 mo and older	Unvaccinated		Pfizer Bivalent: 0.2 mL	Wait 3 weeks	Pfizer Bivalent: 0.2 mL	Wait 4 weeks	Pfizer Bivalent: 0.2 mL	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
		<i>OR</i>						
			Moderna Bivalent: 0.25 mL	Wait 4 weeks	Moderna Bivalent: 0.25 mL	Wait 4 weeks	Moderna Bivalent: 0.25 mL	
	1 dose monovalent Pfizer	Wait 3 weeks	Pfizer Bivalent: 0.2 mL	Wait 4 weeks	Pfizer Bivalent: 0.2 mL	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.		
	2 doses monovalent Pfizer	Wait 4 weeks	Pfizer Bivalent: 0.2 mL	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.				
	3 doses monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.2 mL <i>OR</i> Moderna Bivalent: 0.25 mL	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.				
	3 doses monovalent Pfizer and 1 dose bivalent mRNA (Pfizer or Moderna)		--	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.				
	1 dose monovalent Moderna	Wait 4 weeks	Moderna Bivalent: 0.25 mL	Wait 4 weeks	Moderna Bivalent: 0.25 mL	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.		
	2 doses monovalent Moderna	Wait 4 weeks	Moderna Bivalent: 0.25 mL	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.				
	3 doses monovalent Moderna	Wait 8 weeks	Pfizer Bivalent: 0.2 mL <i>OR</i> Moderna Bivalent: 0.25 mL	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.				
3 doses monovalent Moderna and 1 dose bivalent mRNA (Moderna or Pfizer)		--	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.					

*Heterologous mRNA products may be used for additional doses for this age group. Mixing and matching Pfizer and Moderna is authorized.

Pfizer Additional Doses:

- Pfizer Bivalent Orange Cap (0.2 mL)

Moderna Additional Doses:

- Moderna Bivalent Blue Cap (0.25 mL)

COVID-19 Vaccine Recommendations

Immunocompromised Teens and Adults: Ages 12 years and older

Date: April 19, 2023



Ages: 12 years and older								
	COVID-19 Vaccine History							
Pfizer Cap: Gray Age: 12 years and older	Unvaccinated		Pfizer Bivalent: 0.3 mL	Wait 3 weeks	Pfizer Bivalent: 0.3 mL	Wait 4 weeks	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL	Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
			OR					
Moderna Cap: Dark Blue Label: Gray Age: 6 mo and older		1 dose monovalent Pfizer	Wait 3 weeks	Pfizer Bivalent: 0.3 mL	Wait 4 weeks	Pfizer Bivalent: 0.3 mL		Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
		2 doses monovalent Pfizer	Wait 4 weeks	Pfizer Bivalent: 0.3 mL				Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
		3 doses monovalent Pfizer	Wait 8 weeks	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL				Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
		3 doses monovalent Pfizer and 1 dose <i>bivalent</i> mRNA (Pfizer or Moderna)		--				Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
		1 dose monovalent Moderna	Wait 4 weeks	Moderna Bivalent: 0.5 mL	Wait 4 weeks	Moderna Bivalent: 0.5 mL		Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
		2 doses monovalent Moderna	Wait 4 weeks	Moderna Bivalent: 0.5 mL				Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
		3 doses monovalent Moderna	Wait 8 weeks	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL				Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.
		3 doses monovalent Moderna and 1 dose <i>bivalent</i> mRNA (Moderna or Pfizer)		--				Additional doses may be administered at least 2 months after last dose of bivalent mRNA vaccine.

*Heterologous mRNA products may be used for additional doses for this age group. Mixing and matching Pfizer and Moderna is authorized.

Pfizer Additional Doses:

- Pfizer Bivalent Gray Cap (0.3 mL)

Moderna Additional Doses:

- Moderna Bivalent Blue Cap (0.5 mL)

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2c. **People Who are Moderately to Severely Immunocompromised**

Novavax* (Monovalent vaccine) Type: Protein Sub-Unit			
Age	Vaccination History	Vaccine Schedule	Administer
12 years and older	1 or more doses of monovalent Novavax vaccine	1 dose bivalent mRNA vaccine at least 8 weeks (2 months) after Dose 2 [†]	Moderna: 0.50 mL/50 ug from the vial with a blue cap and gray label border. OR Pfizer-BioNTech: 0.3 mL/30 ug from the vial with a gray cap

* Novavax COVID-19 Vaccine remains authorized to provide a 2-dose primary series (separated by at least 4–8 weeks) to people ages 12 years and older. Administer 0.5 mL/5 µg rS and 50 µg of Matrix-M™ adjuvant vaccine from a vial with a royal blue cap. A booster dose is authorized in limited situations to people ages 18 years and old who completed the primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable (i.e., vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a dose. This dose is administered at least 6 months after completion of any primary series.

† People who are moderately or severely immunocompromised have the option to receive 1 additional dose of a bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose. Refer to CDC's Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance.

COMMON QUESTIONS

When Are You Up to Date?

Everyone aged 6 years and older

You are up to date when you get 1 updated Pfizer-BioNTech or Moderna COVID-19 vaccine.

People who are unable or choose not to get a recommended mRNA vaccine

You are up to date when you get the Novavax COVID-19 vaccine doses approved for your age group.

QUESTIONS

Where can I find this information?

- ALL of the recommendations and guidelines are available on the CDC's website.
 - Direct Link: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- Charts with updated guidelines will be available on the Immunize Arkansas website.
 - Direct Link: <https://www.immunizear.org/covid-19-provider-resources>
- Pfizer EUA: <https://www.fda.gov/media/167211/download>
- Moderna EUA: <https://www.fda.gov/media/167208/download>

RESOURCES

- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/index.html>
- <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines>
- <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines#additional>
- <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines>
- https://emergency.cdc.gov/coca/calls/2023/callinfo_051123.asp
- <https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf>